Based on the LivaNova PLC stock forecast from 6 analysts, the average analyst target price for LivaNova PLC is USD 67.60 over the next 12 months. LivaNova PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of LivaNova PLC is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, LivaNova PLC’s stock price was USD 37.02. LivaNova PLC’s stock price has changed by -11.27% over the past week, -23.69% over the past month and -31.10% over the last year.
No recent analyst target price found for LivaNova PLC
No recent average analyst rating found for LivaNova PLC
Company Overview LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom. Read Less
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells ...Read More
Frequently Asked Questions About LivaNova PLC (LIVN) Stock
Based on ratings from 6 analysts LivaNova PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on LIVN's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for LIVN is USD 67.60 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 55.
LIVN stock's Price/Earning ratio is 35.89.
Our analysis grades LIVN stock's Price / Earning ratio at F. This means that LIVN stock's Price/Earning ratio is above 53% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this LIVN may be a overvalued for its sector.
The last closing price of LIVN's stock was USD 37.02.
The most recent market capitalization for LIVN is USD 2.26B.
Based on targets from 6 analysts, the average taret price for LIVN is projected at USD 67.60 over the next 12 months.
This means that LIVN's stock price may go up by +82.60% over the next 12 months.
We can't find any ETFs which contains LivaNova PLC's stock.
As per our most recent records LivaNova PLC has 2,900 Employees.
LivaNova PLC's registered address is 20 Eastbourne Terrace, London, United Kingdom, W2 6LG.
You can get more information about it from LivaNova PLC's website at https://www.livanova.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About LivaNova PLC (LIVN) Stock
Based on ratings from 6 analysts LivaNova PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on LIVN's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for LIVN is USD 67.60 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 55.
LIVN stock's Price/Earning ratio is 35.89.
Our analysis grades LIVN stock's Price / Earning ratio at F. This means that LIVN stock's Price/Earning ratio is above 53% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this LIVN may be a overvalued for its sector.
The last closing price of LIVN's stock was USD 37.02.
The most recent market capitalization for LIVN is USD 2.26B.
Based on targets from 6 analysts, the average taret price for LIVN is projected at USD 67.60 over the next 12 months.
This means that LIVN's stock price may go up by +82.60% over the next 12 months.
We can't find any ETFs which contains LivaNova PLC's stock.
As per our most recent records LivaNova PLC has 2,900 Employees.
LivaNova PLC's registered address is 20 Eastbourne Terrace, London, United Kingdom, W2 6LG.
You can get more information about it from LivaNova PLC's website at https://www.livanova.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LIVN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
